Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Hodgkin Disease × pertuzumab × 30 days × Clear all

Sponsor

Conditions

Breast Neoplasms 9 Neoplasms 3 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 HER2-positive Breast Cancer 2 Triple Negative Breast Neoplasms 1 Resectable HER2-positive Breast Cancer 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Malignant Solid Neoplasm 1 Hemangiosarcoma 1 HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients 1 HER2-positive Early Breast Cancer 1 Endometrial Neoplasms 1 Brain Neoplasms 1 Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Cyclophosphamide 9 fludarabine phosphate 5 fludarabine 5 Magnetic Resonance Spectroscopy 4 Filgrastim 4 Etoposide 4 Doxorubicin 4 Vincristine 3 Vinblastine 3 Rituximab 3 Prednisone 3 Nivolumab 3 Gemcitabine 3 Dacarbazine 3 Bleomycin 3 pembrolizumab 2 Specimen Handling 2 Radiotherapy 2 Prednisolone 2 Mycophenolic Acid 2 Mesna 2 Melphalan 2 Lenalidomide 2 Granulocyte Colony-Stimulating Factor 2 Cisplatin 2 Brentuximab Vedotin 2 Blood Specimen Collection 2 treosulfan 1 tislelizumab 1 thymoglobulin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡